Annovis Bio (ANVS)

Annovis Bio (ANVS) Stock Price & Analysis


ANVS Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$9.34 - $23.91
Previous Close$13.1
Average Volume (3M)85.38K
Market Cap
Enterprise Value$97.79M
Total Cash (Recent Filing)$16.76M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-3.7
Aug 07, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.57
Shares Outstanding9,005,131
10 Day Avg. Volume34,168
30 Day Avg. Volume85,377
Standard Deviation0.39
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.31
Price Target Upside151.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Annovis Bio’s price range in the past 12 months?
Annovis Bio lowest stock price was $9.34 and its highest was $23.91 in the past 12 months.
    What is Annovis Bio’s market cap?
    Currently, no data Available
    When is Annovis Bio’s upcoming earnings report date?
    Annovis Bio’s upcoming earnings report date is Aug 07, 2023 which is in 67 days.
      How were Annovis Bio’s earnings last quarter?
      Currently, no data Available
      Is Annovis Bio overvalued?
      According to Wall Street analysts Annovis Bio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
        Does Annovis Bio pay dividends?
        Annovis Bio does not currently pay dividends.
        What is Annovis Bio’s EPS estimate?
        Annovis Bio’s EPS estimate is -$1.14.
          How many shares outstanding does Annovis Bio have?
          Annovis Bio has 9,005,131 shares outstanding.
            What happened to Annovis Bio’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Annovis Bio?
            Currently, no hedge funds are holding shares in ANVS


            Annovis Bio Stock Smart Score

            The Annovis Bio stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
            Learn more about TipRanks Smart Score

            Company Description

            Annovis Bio

            Annovis Bio Inc is a United States based clinical stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neuro degenerative diseases. The pipeline products of the company include ANVS-401, ANVS-405 and ANVS-301.


            Top 5 ETFs holding ANVS

            Market Value
            Smart Score
            Vanguard Total Stock Market ETF
            iShares Core S&P Total U.S. Stock Market ETF
            Up to five ETFs with an Outperform Smart Score that hold ANVS. The ETFs are listed according to market value of ANVS within the ETF


            Forecast EPS vs Actual EPS

            Currently, no data available
            Please return soon. This page is being updated.

            Similar Stocks
            Price & Change
            Olema Pharmaceuticals
            Nuvectis Pharma
            Senti Biosciences
            Candel Therapeutics

            Popular Stocks

            What's Included in PREMIUM?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis